Real-world dry eye study shows long-term efficacy of cyclosporine A 0.1% cationic emulsion
Click Here to Manage Email Alerts
Real-world outcomes from the PERSPECTIVE study showed long-term efficacy of cyclosporine A 0.1% cationic emulsion in controlling severe keratitis in patients with dry eye disease.
The study was conducted in 44 clinics across Europe and included 472 patients with dry eye disease (DED) who were nonresponsive to previous treatment with artificial tears. Corneal fluorescein staining (CFS) score was significantly reduced at all study visits from week 4 through month 12.
“DED is an increasingly common condition that affects approximately 11% to 30% of people in Europe and has a heavy impact on the quality of life of sufferers, often leading to loss of productivity and inability to perform daily tasks. Yet, DED is often underrecognized and undertreated, leading to progressive worsening and permanent damage,” study author Gerd Geerling, MD, told Healio/OSN.
The TFOS DEWS II guidelines and other expert consensus recommendations support the use of anti-inflammatory medications early in the disease pathway. Corticosteroids are effective but not recommended for long-term treatment due to the risk for severe complications. In contrast, cyclosporine A can be safely administered for long-term treatment of inflammation.
In the study, patients were instructed to use one drop of cyclosporine A 0.1% cationic emulsion (Santen) in both eyes at bedtime every day for 12 months.
The CFS score was significantly reduced at week 4 and incrementally improved over the 12 months of the study. Mean CFS improved from 2.56 at baseline to 1.10 at 12 months, representing a statistically significant mean change of 1.42 from baseline. Overall, at month 12, 77.5% of patients showed reductions in CFS score ofone grade or more, 47.5% showed reductions oftwo grades or more and 16.7% demonstrated reductions ofthree grades or more. Other signs, including eyelid and conjunctival erythema, were also significantly reduced, and more than 83% of patients reported significant and stable improvement of subjective symptoms up to 12 months. Increases in visual acuity and tear breakup time were equally significant.
“As a chronic disease, DED requires long-term treatment. Our study provided real-world evidence that [cyclosporine A] 0.1% provides sustained improvement in the signs and symptoms of dry eye and keratitis,” Geerling said.
Collapse
Read more about
Click Here to Manage Email Alerts